Article: Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleQuantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment
AuthorsFung, J1
Lai, CL1
Young, J1
Wong, DKH1
Yuen, J1
Seto, WK1
Yuen, MF1
Issue Date2011
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
CitationAmerican Journal Of Gastroenterology, 2011, v. 106 n. 10, p. 1766-1773 [How to Cite?]
DOI: http://dx.doi.org/10.1038/ajg.2011.253
AbstractObjectives: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response in chronic hepatitis B patients treated with entecavir 0.5 mg daily for 2 years. Methods: A total of 166 patients were included. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, and quantitative HBsAg levels were performed at baseline, year 1, and year 2 after commencing entecavir. Additional HBsAg levels were measured at 12 and 24 weeks in patients with available sera. Results: In all, 68 patients were hepatitis B e-antigen (HBeAg) positive. Age, HBV DNA, and alanine aminotransferase (ALT) were significantly correlated with HBsAg levels at baseline (r=-0.429, 0.607, and 0.254, respectively, all P<0.05). The correlation with HBV DNA and ALT levels was reduced by entecavir treatment, and was lost after 2 years of treatment. There was an overall decline in HBsAg levels from baseline to year 1 to year 2 (3,377.4 vs. 2,316.5 vs. 1,903.0 IU/ml, respectively, P<0.001). However, at year 2, 102 patients (61%) had no significant changes (<0.5 log difference), 50 (30%) had significant decline (≥0.5 log decrease), whereas 14 (9%) had significant increase (0.5 log increase). Of the patients, 151 (91%) had undetectable HBV DNA; 25 (37%) underwent HBeAg seroconversion. Neither HBsAg at baseline nor early decline at weeks 12 or 24 was predictive of HBeAg seroconversion at 2 years. Conclusions: Despite HBV DNA suppression, the majority did not show significant decline in HBsAg levels. Early decline of HBsAg levels at 12/24 weeks was not associated with HBV DNA suppression or HBeAg seroconversion. © 2011 by the American College of Gastroenterology.
ISSN0002-9270
2011 Impact Factor: 7.282
2011 SCImago Journal Rankings: 0.573
DOIhttp://dx.doi.org/10.1038/ajg.2011.253
ISI Accession Number IDWOS:000295926600005
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorFung, J
dc.contributor.authorLai, CL
dc.contributor.authorYoung, J
dc.contributor.authorWong, DKH
dc.contributor.authorYuen, J
dc.contributor.authorSeto, WK
dc.contributor.authorYuen, MF
dc.date.accessioned2011-10-28T02:44:56Z
dc.date.available2011-10-28T02:44:56Z
dc.date.issued2011
dc.description.abstractObjectives: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response in chronic hepatitis B patients treated with entecavir 0.5 mg daily for 2 years. Methods: A total of 166 patients were included. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, and quantitative HBsAg levels were performed at baseline, year 1, and year 2 after commencing entecavir. Additional HBsAg levels were measured at 12 and 24 weeks in patients with available sera. Results: In all, 68 patients were hepatitis B e-antigen (HBeAg) positive. Age, HBV DNA, and alanine aminotransferase (ALT) were significantly correlated with HBsAg levels at baseline (r=-0.429, 0.607, and 0.254, respectively, all P<0.05). The correlation with HBV DNA and ALT levels was reduced by entecavir treatment, and was lost after 2 years of treatment. There was an overall decline in HBsAg levels from baseline to year 1 to year 2 (3,377.4 vs. 2,316.5 vs. 1,903.0 IU/ml, respectively, P<0.001). However, at year 2, 102 patients (61%) had no significant changes (<0.5 log difference), 50 (30%) had significant decline (≥0.5 log decrease), whereas 14 (9%) had significant increase (0.5 log increase). Of the patients, 151 (91%) had undetectable HBV DNA; 25 (37%) underwent HBeAg seroconversion. Neither HBsAg at baseline nor early decline at weeks 12 or 24 was predictive of HBeAg seroconversion at 2 years. Conclusions: Despite HBV DNA suppression, the majority did not show significant decline in HBsAg levels. Early decline of HBsAg levels at 12/24 weeks was not associated with HBV DNA suppression or HBeAg seroconversion. © 2011 by the American College of Gastroenterology.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationAmerican Journal Of Gastroenterology, 2011, v. 106 n. 10, p. 1766-1773 [How to Cite?]
DOI: http://dx.doi.org/10.1038/ajg.2011.253
dc.identifier.doihttp://dx.doi.org/10.1038/ajg.2011.253
dc.identifier.epage1773
dc.identifier.hkuros196659
dc.identifier.hkuros213672
dc.identifier.isiWOS:000295926600005
dc.identifier.issn0002-9270
2011 Impact Factor: 7.282
2011 SCImago Journal Rankings: 0.573
dc.identifier.issue10
dc.identifier.openurl
dc.identifier.pmid21826112
dc.identifier.scopuseid_2-s2.0-80053894414
dc.identifier.spage1766
dc.identifier.urihttp://hdl.handle.net/10722/142389
dc.identifier.volume106
dc.languageeng
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
dc.publisher.placeUnited States
dc.relation.ispartofAmerican Journal of Gastroenterology
dc.relation.referencesReferences in Scopus
dc.subject.meshAntiviral Agents - administration and dosage - therapeutic use
dc.subject.meshGuanine - administration and dosage - analogs and derivatives - therapeutic use
dc.subject.meshHepatitis B Surface Antigens - blood
dc.subject.meshHepatitis B virus - genetics - immunology - isolation and purification
dc.subject.meshHepatitis B, Chronic - drug therapy - enzymology - immunology
dc.titleQuantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong